A role for macrophage migration inhibitory factor in the neonatal respiratory distress syndrome

Journal of Immunology

Volumn 180, Issue 1, 2008, Pages 601-608

  Kevill, Katharine A ^a   Bhandari, Vineet ^a   Kettunen, Mika ^b   Leng, Lin ^a   Fan, Juan ^a   Mizue, Yuka ^a   Dzuira, James D ^a   Reyes Mugica, Miguel ^a   McDonald, Courtney L ^a   Baugh, John A ^b   O'Connor, Christine L ^a   Aghai, Zubair H ^c   Donnelly, Seamas C ^b   Bazzy Asaad, Alia ^a   Bucala, Richard J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c Department of Anesthesiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUNG SURFACTANT; MACROPHAGE MIGRATION INHIBITION FACTOR; CORTICOSTERONE; ISOMERASE; MIF PROTEIN, MOUSE; SURFACTANT ASSOCIATED PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DISEASE MODEL; FEMALE; FETUS LUNG MATURATION; FETUS LUNG MATURITY; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFANT; KNOCKOUT MOUSE; LUNG DYSPLASIA; MACROPHAGE; MALE; MOUSE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREMATURITY; PRIORITY JOURNAL; PUP (RODENT); SURVIVAL RATE; TISSUE LEVEL; WILD TYPE; ANGIOGENESIS; ANIMAL; GENETICS; IMMUNOLOGY; LUNG; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PNEUMONIA; PRENATAL DEVELOPMENT;

ANIMALS; BRONCHOPULMONARY DYSPLASIA; CORTICOSTERONE; DISEASE MODELS, ANIMAL; HUMANS; INFANT, NEWBORN; INTRAMOLECULAR OXIDOREDUCTASES; LUNG; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; PNEUMONIA; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 40449091848     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.1.601     Document Type: Article

References (53)

1. Martin, J. A., K. D. Kochanek, D. M. Strobino, B. Guyer, and M. F. MacDorman. 2005. Annual summary of vital statistics: 2003. Pediatrics 115: 619-634.
2. Bancalari, E., and M. Bidegain. 1999. Respiratory Disorders of the Newborn. In Pediatric Respiratory Medicine. L. Taussig and L. Landau, eds., pp. 464-468.
3. Koivisto, M., R. Marttila, M. Kurkinen-Raty, T. Saarela, M. Pokela, P. Jouppila, and M. Hallmann. 2004. Changing incidence and outcome of infants with respiratory distress syndrome in the 1990's: a population-based survey. Acta Paediatr. 93: 177-184.
4. Fanaroff, A. A., L. L. Wright, D. K. Stevenson, S. Shankaran, E. F. Donovan, R. A. Ehrenkrans, N. Younes, S. B. Korones, B. J. Stoll, J. E. Tyson, et al. 1995. Very-low-birth-weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, May 1991 through December 1992. Am. J. Obstet. Gynecol. 173: 1423-1431.
5. Jobe, A. J. 1999. The new BPD: An arrest of lung development. Pediatric Research 46: 641-643.
6. Schaubel, D., H. Johansen, M. Dutta, M. Desmeules, A. Becker, and Y. Mao. 1996. Neonatal characteristics as risk factors for preschool asthma. J. Asthma. 33: 255-264.
7. Whitsett, J. A., S. E. Wert, and B. C. Trapnell. 2004. Genetic disorders influencing lung formation and function at birth. Hum. Mol. Genet. 13: R207-R215.
8. Kaplan, F. 2000. Molecular determinants of fetal lung organogenesis. Mol. Genet. Metab. 71: 321-341.
9. Watterberg, K., L. Demers, S. Scott, and S. Murphy. 1996. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97: 210-215.
10. Shimoya, K., T. Taniguchi, N. Matsuzaki, A. Moriyama, Y. Murata, H. Kitajima, F. M., and M. Nakayama. 2000. Chorioamnionitis decreased incidence of respiratory distress syndrome by elevating fetal interleukin-6 serum concentration. Hum. Reprod. 15: 2234-2240.
11. Bry, K., U. Lappalainen, and M. Hallman. 1997. Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth. J. Clin. Invest. 99: 2992-2999.
12. Jobe, A. H., J. P. Newnham, K. E. Willet, P. Sly, M. G. Ervin, C. Bachurski, F. Possmayer, M. Hallman, and M. Ikegami. 2000. Effects of antenatal endotoxin and glucocorticoids on the lungs of preterm lambs. Am. J. Obstet. Gynecol. 182: 401-408.
13. Jobe, A. H., and M. Ikegami. 2000. Lung development and function in preterm infants in the surfactant treatment era. Annu. Rev. Physiol. 62: 825-846.
14. Munshi, U., J. Niu, M. Siddiq, and L. A. Parton. 2004. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatric Pulmonol. 24: 331-336.
15. Calandra, T., and T. Roger. 2003. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3: 791-800.
16. Bernhagen, J., T. Calandra, R. A. Mitchell, S. B. Martin, K. J. Tracey, W. Voelter, K. R. Manogue, A. Cerami, and R. Bucala. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759.
17. Donnelly, S. C., C. Haslett, P. T. Reid, I. S. Grant, W. A. Wallace, C. N. Metz, L. J. Bruce, and R. Bucala. 1997. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat. Med. 3: 320-323.
18. Rossi, A. G., C. Haslett, N. Hirani, A. P. Greening, I. Rahman, C. N. Metz, R. Bucala, and S. C. Donnelly. 1998. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF): potential role in asthma. J. Clin. Invest. 101: 2869-2874.
19. Bozza, M., A. R. Satoskar, G. Lin, B. Lu, A. A. Humbles, C. Gerard, and J. R. David. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189: 341-346.
20. Mizue, Y., S. Ghani, L. Leng, C. McDonald, P. Kong, J. Baugh, S. J. Lane, J. Craft, J. Nishihira, S. C. Donnelly, et al. 2005. Role for macrophage migration inhibitory factor (MIF) in asthma. Proc. Natl. Acad. Sci. USA 102: 14410-14415.
21. Makita, H., M. Nishimura, K. Miyamoto, T. Nakano, Y. Tanino, J. Hirokawa, J. Nishihira, and Y. Kawakami. 1998. Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am. J. Resp. Crit. Care Med. 158: 573-579.
22. Roger, T., J. David, M. P. Glauser, and T. Calandra. 2001. MIF regulates innate immune responses through modulation of toll-like receptor 4. Nature 414: 920-924.
23. Ren, Y., H. M. Chan, Z. Li, C. L. Lin, J. Nicholls, C. F. Chen, P. Y. Lee, V. Lui, M. Bacher, and P. K. Tam. 2004. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene 23: 4146-4154.
24. Warburton, D., C. Wuenschell, G. Flores-Delgado, and K. Anderson. 1998. Commitment and differentiation of lung cell lineages. Biochem. Cell Biol. 76: 971-995.
25. Fingerle-Rowson, G., O. Petrenko, C. N. Netz, T. G. Forsthuber, R. Mitchell, R. Huss, U. Moll, W. Müller, and R. Bucala. 2003. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc. Natl. Acad. Sci. USA 100: 9354-9359.
26. Compernolle, V., K. Brusselmans, T. Acker, P. Hoet, M. Tjwa, H. Beck, S. Plaisance, Y. Dor, E. Keshet, F. Lupu, et al. 2002. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8: 702-710.
27. Bacher, M., A. Meinhardt, H. Y. Lan, W. Mu, C. N. Metz, J. A. Chesney, T. Calandra, D. Gemsa, T. Donnelly, R. C. Atkins, and R. Bucala. 1997. Migration inhibitory factor expression in experimentally induced endotoxemia. Am. J. Pathol. 150: 235-246.
28. O'Reilly, M. A., J. C. Clark, and J. A. Whitsett. 1991. Glucocorticoid enhances pulmonary surfactant protein B gene transcription. Am. J. Physiol. 260: L37-L43.
29. Sun, B., J. Nishihira, T. Yoshiki, M. Kondo, Y. Sato, F. Sasaki, and S. Todo. 2005. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the rho-dependent pathway. Clin. Cancer Res. 11: 1050-1058.
30. Bhandari, A., and V. Bhandari. 2003. Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front. Biosci. 8: E370-E380.
31. Zar, J. H. 1985. Biostatistical Analysis. Prentice-Hall, Englewood Cliffs, NJ.
32. Fingerle-Rowson, G., A. Satoskar, and R. Bucala. 2003. Macrophage migration inhibitory factor (MIF)-deficient mice. In Cytokine Knockouts. G. Fantuzzi, ed. Humana Press, Totowa, pp. 361-378.
33. Kobayashi, S., K. Satomura, J. M. Levsky, T. Sreenath, G. J. Wistow, I. Semba, L. Shum, H. C. Slavkin, and A. B. Kulkarni. 1999. Expression pattern of macrophage migration inhibitory factor during embryogenesis. Mech. Dev. 84: 153-156.
34. Jobe, A. H., J. P. Newnham, K. E. Willet, T. J. Moss, M. G. Ervin, J. F. Padbury, P. Sly, and M. Ikegami. 2000. Endotoxin-induced lung maturation in preterm lambs is not mediated by cortisol. Am. J. Respir. Crit. Care Med. 162: 1656-1661.
35. Mitchell, R. A., H. Liao, J. Chesney, G. Fingerle-Rowson, J. Baugh, J. David, and R. Bucala. 2002. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA 99: 345-350.
36. Carmeliet, P., V. Ferreira, G. Breier, S. Pollefeyt, L. Kieckens, M. Gertsenstein, M. Fahrig, A. Vandenhoeck, K. Harpal, C. Eberhardt, et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
37. Weaver, T. E., and J. A. Whitsett. 1991. Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem. J. 273: 249-264.
38. Kauffman, S. L. 1977. Acceleration of canalicular development in lungs of fetal mice exposed transplacentally to dexamethasone. Lab. Invest. 36: 395-401.
39. Jobe, A. H., J. P. Newnham, K. E. Willet, T. J. Moss, M. G. Ervin, J. F. Padbury, P. Sly, and M. Ikegami. 2000. Endotoxin-induced lung maturation in preterm lambs is not mediated by cortisol. Am. J. Respir. Crit. Care Med. 162: 1656-1661.
40. Speirs, H. J., J. R. Seckl, and R. W. Brown. 2004. Ontogeny of glucocorticoid receptor and 11 β-hydroxysteroid dehydrogenase type-1 gene expression identifies potential critical periods of glucocorticoid susceptibility during development. J. Endocrinol. 181: 105-116.
41. Calandra, T., J. Bernhagen, C. N. Metz, L. A. Spiegel, M. Bacher, T. Donnelly, A. Cerami, and R. Bucala. 1995. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377: 68-71.
42. Daun, J. M., and J. G. Cannon. 2000. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IκBα. Am. J. Physiol. 279: R1043-R1049.
43. Fingerle-Rowson, G., P. Koch, R. Bikoff, X. Lin, C. N. Metz, F. S. Dhabhar, A. Meinhardt, and R. Bucala. 2003. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am. J. Pathol. 162: 47-56.
44. Roger, T., A. L. Chanson, M. Knaup-Reymond, and T. Calandra. 2005. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur. J. Immunol. 35: 3405-3413.
45. Yang, N. S., D. J. Nikolic-Paterson, Y. Y. Ng, W. Mu, C. Metz, M. Bacher, A. Meinhardt, R. Bucala, R. C. Atkins, and H. Y. Lan. 1998. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol. Med. 4: 413-424.
46. Newnham, J., T. Moss, J. Padbury, K. Willet, M. Ikegami, M. Ervin, P. Sly, and A. Jobe. 2001. The interactive effects of endotoxin with prenatal glucocorticoids on short-term lung function in sheep. Am. J. Obstet. Gynecol. 185: 190-197.
47. Li, M. O., M. R. Sarkisian, W. Z. Mehal, P. Rakic, and R. A. Flavell. 2003. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science 302: 1560-1563.
48. Han, R. N., S. Babaei, M. Robb, T. Lee, R. Ridsdale, C. Ackerley, M. Post, and D. J. Stewart. 2004. Defective lung vascular development and fatal respiratory distress in endothelial NO synthase-deficient mice: a model of alveolar capillary dysplasia? Circ. Res. 94: 1115-1123.
49. Ietta, F., T. Todros, C. Ticconi, E. Piccoli, A. Zicari, E. Piccione, and L. Paulesu. 2002. Macrophage migration inhibitory factor in human pregnancy and labor. Am. J. Reprod. Immunol. 48: 404-409.
50. Chesney, J., C. Metz, M. Bacher, T. Peng, A. Meinhardt, and R. Bucala. 1999. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5: 181-191.
51. Amin, M. A., O. V. Volpert, J. M. Woods, P. Kumar, L. A. Harlow, and A. E. Koch. 2003. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ. Res. 93: 321-329.
52. Lassus, P., I. Nupponen, A. Kari, M. Pohjavuori, and S. Andersson. 2002. Early postnatal dexamethasone decreases hepatocyte growth factor in tracheal aspirate fluid from premature infants. Pediatrics 110: 768-771.
53. Plant, B. J., C. G. Gallagher, R. Bucala, J. A. Baugh, S. Chappell, L. Morgan, C. M. O'Connor, K. Morgan, and S. C. Donnelly. 2005. Cystic fibrosis, disease severity and a macrophage migration inhibitory factor polymorphism. Am. J. Respir. Crit. Care Med. 172: 1412-1415.